Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites

Apicomplexan infections cause substantial morbidity and mortality, worldwide. New, improved therapies are needed. Herein, we create a next generation anti-apicomplexan lead compound, JAG21, a tetrahydroquinolone, with increased sp3-character to improve parasite selectivity. Relative to other cytochr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Cell Infect Microbiol
Autores principales: McPhillie, Martin J., Zhou, Ying, Hickman, Mark R., Gordon, James A., Weber, Christopher R., Li, Qigui, Lee, Patty J., Amporndanai, Kangsa, Johnson, Rachel M., Darby, Heather, Woods, Stuart, Li, Zhu-hong, Priestley, Richard S., Ristroph, Kurt D., Biering, Scott B., El Bissati, Kamal, Hwang, Seungmin, Hakim, Farida Esaa, Dovgin, Sarah M., Lykins, Joseph D., Roberts, Lucy, Hargrave, Kerrie, Cong, Hua, Sinai, Anthony P., Muench, Stephen P., Dubey, Jitender P., Prud'homme, Robert K., Lorenzi, Hernan A., Biagini, Giancarlo A., Moreno, Silvia N., Roberts, Craig W., Antonyuk, Svetlana V., Fishwick, Colin W. G., McLeod, Rima
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2020
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7311950/
https://ncbi.nlm.nih.gov/pubmed/32626661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcimb.2020.00203
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares